TGFB1 and endometrial cancer: In our in vivo study, the serum level of TGF-β was remarkably down-regulated after ISL treatment, while the TGF-β typeIreceptor was not significantly changed between the two groups, thus we speculate that 10 mg/kg of ISL has the potential to reduce TGF-β levels in endometrial cancer, but this dose may not be enough to affect the expression level of its receptor.